UK NICE issues draft guidance not recommending Imlygic (talimogene laherparepvec) for metastatic melanoma that can't be surgically removed- Amgen

NICE has issued draft guidance not recommending Imlygic (talimogene laherparepvec), from Amgen, as an option for people with melanoma that has spread and can’t be surgically removed. The committee concluded that there was not enough evidence to be able to say whether talimogene laherparepvec is as clinically effective as other drugs used to treat advanced melanoma. Given the uncertainty about its effect on overall survival compared with these drugs it was not possible to recommend talimogene laherparepvec as a cost-effective use of NHS resources.